Study #2015-0693
A Single Arm Study of 6-months Neoadjuvant Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features that Drive Post-Operative Radiation Therapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Apalutamide
Description
This phase II trial studies how well apalutamide works in treating patients with prostate cancer before radical prostatectomy. Androgen can cause the growth of prostate cancer cells. Hormone therapy using apalutamide may fight prostate cancer by lowering the amount of androgen the body makes and may make it less likely for patients to receive radiation therapy after surgery.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Study phase:
Phase II
Physician name:
John Davis
Department:
Urology
For general questions about clinical trials:
1-866-599-0508
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.